Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 299.89 |
| Low | 299.89 |
| Bid | -- |
| Offer | -- |
| Previous close | 237.27 |
| Average volume | -- |
|---|---|
| Shares outstanding | 113.79m |
| Free float | 100.98m |
| P/E (TTM) | -- |
| Market cap | 1.56bn USD |
| EPS (TTM) | -1.61 USD |
Data delayed at least 20 minutes, as of Oct 02 2023 12:30 BST.
More ▼
Press releases
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
- Novocure to Participate in 2026 Leerink Global Healthcare Conference
- Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
- Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
- U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
- Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
- Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
More ▼
